

Local Coverage Determination (LCD): Treatment of Varicose Veins of the Lower Extremities (L34010)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATE(S)
Noridian Healthcare Solutions, LLC	A and B MAC	02101 - MAC A	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02102 - MAC B	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02201 - MAC A	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02202 - MAC B	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02301 - MAC A	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02302 - MAC B	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02401 - MAC A	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	02402 - MAC B	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	03101 - MAC A	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03102 - MAC B	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03201 - MAC A	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03202 - MAC B	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03301 - MAC A	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03302 - MAC B	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03401 - MAC A	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03402 - MAC B	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03501 - MAC A	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03502 - MAC B	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03601 - MAC A	J - F	Wyoming
Noridian Healthcare Solutions, LLC	A and B MAC	03602 - MAC B	J - F	Wyoming

LCD Information

Document Information

LCD ID
L34010

Original Effective Date

For services performed on or after 10/01/2015

LCD Title

Revision Effective Date

Treatment of Varicose Veins of the Lower Extremities

For services performed on or after 12/01/2019

Proposed LCD in Comment Period

N/A

Revision Ending Date

N/A

Source Proposed LCD

N/A

Retirement Date

N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Notice Period Start Date

01/27/2016

Notice Period End Date

03/12/2016

Current Dental Terminology © 2019 American Dental Association. All rights reserved.

Copyright © 2019, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com.

CMS National Coverage Policy

Language quoted from CMS National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review a NCD. See §1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act, §1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Title XVIII of the Social Security Act, §1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

CMS Manual System, Pub 100-08, *Medicare Program Integrity Manual*, Chapter 13, §13.5.1 indicates services will be considered medically reasonable and necessary only if ordered and furnished by appropriately trained personnel.

This training and expertise must have been acquired within the framework of an accredited residency and/or fellowship program in the applicable specialty/subspecialty or must reflect extensive continued medical education activities. If these skills have been acquired by way of continued medical education, the courses must be comprehensive, offered or sponsored or endorsed by an academic institution in the United States and/or by the applicable specialty/subspecialty society in the United States, and designated by the American Medical Association (AMA) as Category 1 Credit.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Varicose veins are caused by venous insufficiency as a result of valve reflux (incompetence). The venous insufficiency results in dilated, tortuous, superficial vessels that protrude from the skin of the lower extremities. Spider veins (telangiectasias) are dilated capillary veins that are most often treated for cosmetic purposes. Treatment of telangiectasias is not covered by Medicare.

Historically, varicose veins have been treated by conservative measures such as exercise, periodic leg elevation, weight loss, compressive therapy and avoidance of prolonged immobility. When conservative measures are unsuccessful, and symptoms persist, the next step has been sclerotherapy or surgical ligation with or without stripping. Sclerotherapy involves the injection of a sclerosing solution into the varicose vein(s).

Compressive sclerotherapy is the injection of the sclerosant into an empty vein (elevated limb) followed by application of a compressive bandage or dressing. This is the most commonly performed sclerotherapy procedure for varicose veins of the lower extremity. Compressive sclerotherapy is indicated for local small to medium symptomatic varices, isolated incompetent perforators, or recurrence of symptomatic varices after adequate surgical removal of varices. It is not considered an appropriate option for large, extensive or truncal varicosities. Foam sclerotherapy is FDA indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. It is usually given with ultrasound guidance. Non-Compressive sclerotherapy is not covered by Medicare.

More recently, endoluminal radiofrequency ablation (ERFA) and endoluminal laser ablation have been developed as alternatives to sclerotherapy and surgical intervention. These procedures are designed to damage the intimal wall of the vein resulting in fibrosis and subsequent ablation of the lumen of a segment of the vessel. Both procedures utilize specially designed catheters inserted through a small incision in the distal thigh and advanced, often under ultrasound guidance, nearly to the saphenofemoral junction. The catheter is then slowly withdrawn while controlled radiofrequency or laser energy is applied. This is followed by external compression of the treated segment.

Doppler ultrasound or duplex studies are often used to map the anatomy of the venous system prior to the

procedure. There is adequate evidence that pre-procedural ultrasound is helpful, and Medicare will cover one ultrasound or duplex scan prior to the procedure to determine the extent and configuration of the varicosities.

Evidence and clinical experience supports the use of ultrasound guidance during the procedure (ERFA and laser ablation only) and shows that the outcomes may be improved and complication rates may be minimized when ultrasound guidance is used. The CPT codes for radiofrequency and laser include the intraoperative ultrasound service in the valuation and ultrasound may not be billed separately with these procedures.

In contrast to ERFA and laser procedures, intra-operative ultrasound guidance techniques have not been shown to increase the effectiveness or safety of sclerotherapy for varicose veins, therefore, intra-operative ultrasound guidance will not be separately covered for sclerotherapy.

A. Indications for surgical treatment: For example venous ligation, vein stripping and/or sclerotherapy.

1. A 3-month trial of conservative therapy such as exercise, periodic leg elevation, weight loss, compressive therapy, and avoidance of prolonged immobility where appropriate, has failed, **AND**
2. The patient is symptomatic and has one, or more, of the following:
 - a. Pain or burning in the extremity severe enough to impair mobility
 - b. Recurrent episodes of superficial phlebitis
 - c. Non-healing skin ulceration
 - d. Bleeding from a varicosity
 - e. Stasis dermatitis
 - f. Refractory dependent edema

B. Indications for ERFA or laser ablation

In addition to the above (see A), the patient's anatomy and clinical condition are amenable to the proposed treatment including **ALL** of the following:

1. Absence of aneurysm in the target segment.
2. Maximum vein diameter of 12 mm for ERFA or 20 mm for laser ablation
3. Absence of thrombosis or vein tortuosity, which would impair catheter advancement.
4. The absence of significant peripheral arterial diseases.

C. Limitations for ERFA and laser ablation:

1. ERFA and laser ablation are covered only for the treatment of symptomatic varicosities of the lesser or greater saphenous veins and their tributaries which have failed 3 months of conservative therapy.
2. Intra-operative ultrasound guidance is not separately payable with ERFA, laser ablation, and sclerotherapy.
3. The treatment of asymptomatic varicose veins, or symptomatic varicose veins without a 3-month trial of conservative measures, by any technique will be considered cosmetic and therefore not covered.
4. The treatment of spider veins or superficial telangiectasis by any technique is considered cosmetic, and therefore not covered.
5. Coverage is only for devices specifically FDA-approved for these procedures.
6. One pre-operative Doppler ultrasound study or duplex scan will be covered.

Noridian notes that stab phlebectomy of the same vein performed on the same day as endovenous radiofrequency or laser ablation may be covered if the criteria for reasonable and necessary as described in this LCD are met.

Noridian notes that if sclerotherapy is used with endovenous radiofrequency ablation, it may be covered if the criteria for reasonable and necessary as described in this LCD are met.

Noridian will not consider the treatment of asymptomatic veins with endoluminal ablation or sclerotherapy medically reasonable and necessary. If it is determined on review that the varicose veins were asymptomatic, the claim will be denied as a noncovered (cosmetic) procedure.

Compliance with the provisions in this policy is subject to monitoring by post payment data analysis and subsequent medical review.

Summary of Evidence

N/A

Analysis of Evidence (Rationale for Determination)

N/A

General Information

Associated Information

1. Each claim must be submitted with an ICD-10-CM code(s) that reflects the condition of the patient and indicates the reason(s) for which the service was performed.
2. The patient's medical record must contain a history and physical examination supporting the diagnosis of symptomatic varicose veins, and the failure of an adequate (at least 3 months) trial of conservative management.
3. The medical record must document the performance of appropriate tests, if medically necessary, to confirm the pathology of the vascular anatomy.
4. This documentation must be made available to Medicare upon request.
5. The HCPCS/CPT code(s) may be subject to Correct Coding Initiative (CCI) edits. This policy does not take precedence over CCI edits. Please refer to the CCI for correct coding guidelines and specific applicable code combinations prior to billing Medicare.
6. When the documentation does not meet the criteria for the service rendered or the documentation does not establish the medical necessity for the services, such services will be denied as not reasonable and necessary under Section 1862(a)(1) of the Social Security Act.

Sources of Information

Refer to Bibliography

Bibliography

1. Other carrier policies including those from Empire, *HGSA and CIGNA*.
2. Manufacturer's Literature. *VNUS Medical Technologies, Inc.*
3. Chandler JG, Pichot O, Sessa C, et al. Treatment of primary venous insufficiency by endovenous saphenous vein obliteration. *Vasc Surg* 2000; 34:201-14.
4. Goldman M. Closure of the greater saphenous vein with endoluminal radiofrequency thermal heating of the vein wall in combination with ambulatory phlebectomy: preliminary 6 month follow-up. *Dermatol Surg* 2000; 26:452-56.
5. Kabnick LS, Merchant RF. Twelve and twenty-four months follow-up after endovascular obliteration of saphenous vein reflux - A report from the multi-center registry. *J Phlebology* 2001; 1:17-24.
6. Merchant RF, DePalma RG, Kabnick LS. Endovascular obliteration of saphenous reflux: a multicenter study. *J Vasc Surg* 2002; 35(6): 1190-6.
7. Fassiadis N, Kianifard B, Holdstock JM, Whiteley MS. A novel approach to the treatment of recurrent varicose veins. *Int Angiol*, 2002 Sep; 21(3): 275-6. Abstract. PubMed.
8. Forrestal, MD, Min, RJ, et. al. Endovenous Laser Treatment (EVLT) for Varicose Veins-A review. *Today's Therapeutic Trends*, 299-310. Communications Media for Education, Inc., Princeton, New Jersey.
9. Winifred S. Hayes Technology Assessment - Endoluminal Radiofrequency Ablation for Varicose Veins of the Leg. *Winifred S. Hayes, Inc.* June 2002.
10. Lurie F, Creton D, Eklof B et al. Prospective randomized study of endovenous radiofrequency obliteration (closure procedure) versus ligation and stripping in a selected patient population. *J Vasc Surg* 2003; 38:207-14.
11. Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of saphenous vein reflux. Long term results *J Vasc Interv Radiol* 2003;14:991-96.
12. Rautio T, Ohinmaa A, Perala J, Ohtonen P, Heikkinen T, Wiik H, Karjalainen P, Haukipuro K, Juvonen T. Endovenous versus conventional stripping operation in the treatment of primary varicose veins: a randomized controlled trial with comparison of the costs. *J Vasc Surg* 2002 May; 35(5): 958-965.
13. Sybrandy JE, Wittens, CH. Initial experiences in endovenous treatment of saphenous vein reflux. *J Vasc Surg*. 2002 Dec; 36(6): 1207-12. 10. Weiss, R. MD. Varicose Veins Treated with Radiofrequency Ablation Therapy. [Emedicine](#). Accessed April 3, 2003.
14. Noridian Contractor Advisory Committee Members.
15. Todd K., Wright, DI, VANISH-2 Investigator Group. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.35% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. *Phlebology*. [Sage](#)
16. Department of Varicose Vein Clinic, Charm Vein Center, Seoul, Republic of Korea; Initial Outcomes of Cyanoacrylate Closure, VenaSeal System, for the Treatment of the Incompetent Great and Small Saphenous Veins; *Vascular Endovascular Surgery*; 2017 Nov; 51(8):545-549.

17. Lake Washington Vascular Surgeons, Bellevue, WA, USA; Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: Initial outcomes of a post-market evaluation of the VenaSeal System (The WAVES study); *Vascular*; 2017 Apr;25(2):149-156.

18. Bellam Premnath, KP., Joy, B., Raghavendra, VA., Toms, A., Sleeba, T.; Cyanoacrylate adhesive embolization and sclerotherapy for primary varicose veins. *Phlebology*; 2017 Jan 1.

19. Prasad, Bp K., Joy, B., Toms, A., Sleeba, T.; Treatment of incompetent perforators in recurrent venous insufficiency with adhesive embolization and sclerotherapy. *Phlebology*; 2017 Jan 1.

Revision History Information

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE
12/01/2019	R13	<p>The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</p>	<ul style="list-style-type: none"> Other (The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.)
12/01/2019	R12	<p>12/01/2019: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</p> <p>As required by CR 10901, all billing and coding information has been moved to the companion article, this article is linked to the LCD</p>	<ul style="list-style-type: none"> Provider Education/Guidance Revisions Due To Code Removal
01/01/2018	R11	<p>12/7/17: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which</p>	<ul style="list-style-type: none"> Revisions Due To CPT/HCPCS Code Changes

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE
		<p>requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</p> <p>Added 36473 and 36474 to the ICD-10 Codes that Support Medical Necessity section.</p>	
01/01/2018	R10	<p>12/6/17: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy. 2018 CPT Coded added effective 01/01/2018: 36465, 36466, 36482, 36483</p>	<ul style="list-style-type: none"> • Revisions Due To CPT/HCPCS Code Changes
10/01/2017	R9	<p>DATE (08/22/2017): At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</p> <p>Add:</p> <p>I87301 Chronic venous hypertension (idiopathic) without complications of right lower extremity</p> <p>I87302 Chronic venous hypertension (idiopathic) without complications of left lower extremity</p>	<ul style="list-style-type: none"> • Revisions Due To ICD-10-CM Code Changes

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE
		<p>I87303 Chronic venous hypertension (idiopathic) without complications of bilateral lower extremity</p> <p>I87391 Chronic venous hypertension (idiopathic) with other complications of right lower extremity</p> <p>I87392 Chronic venous hypertension (idiopathic) with other complications of left lower extremity</p> <p>I87393 Chronic venous hypertension (idiopathic) with other complications of bilateral lower extremity</p> <p>I878 Other specified disorders of veins</p>	
01/01/2017	R8	Clarification regarding coding under Group 1 Paragraph: 36299* is used for sclerotherapy with mechanical agitation (e.g. Clarivein® device) prior to January 1, 2017. On and after this date use the AMA assigned codes 36473 and 36474 to report this procedure. These codes are inclusive of the sclerosing agent. 37799* should be used to report "Trivex Procedure"	<ul style="list-style-type: none"> • Revisions Due To CPT/HCPCS Code Changes
01/01/2017	R7	2017 CPT updates deleted 93965 effective 12/31/2016	<ul style="list-style-type: none"> • Revisions Due To CPT/HCPCS Code Changes
01/01/2017	R6	2017 coding update to end-date 36299 effective 12/31/2016.	<ul style="list-style-type: none"> • Revisions Due To CPT/HCPCS Code Changes
01/01/2017	R5	2017 CPT Code update to add 36473 and 36474	<ul style="list-style-type: none"> • Revisions Due To CPT/HCPCS Code

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE
			Changes
03/13/2016	R4	This final LCD, effective 03/13/2016, combines JFA L36599 into the JFB LCD so that both JFA and JFB contract numbers will have the same final MCD LCD number.	<ul style="list-style-type: none"> • Creation of Uniform LCDs Within a MAC Jurisdiction
03/13/2016	R3	The LCD is revised editorially to be consistent for both Jurisdictions JE and JF AB MACs. The effective date remains the same.	<ul style="list-style-type: none"> • Creation of Uniform LCDs Within a MAC Jurisdiction • Revisions Due To CPT/HCPCS Code Changes • Typographical Error
03/13/2016	R2	This I-10 version is the result of I-9 DL24375 finalizing in I-10	<ul style="list-style-type: none"> • Creation of Uniform LCDs Within a MAC Jurisdiction
10/01/2015	R1	This LCD is revised to remove the paragraph, "When requesting an individual consideration through the written redetermination (formerly appeal) process, providers must include all relevant medical records and any pertinent peer-reviewed literature that supports the request. At a minimum two (2) Phase II studies (human studies of efficacy, pivotal) or one (1) Phase III study (evidence of safety and efficacy, pivotal) must be submitted for the Medical Director's review." from the Associated Information field.	<ul style="list-style-type: none"> • Other (Removed the paragraph, "When requesting an individual consideration through the written redetermination (formerly appeal) process, providers must include all relevant medical records and any pertinent peer-reviewed literature that supports the request. At a minimum two (2) Phase II studies (human studies of efficacy, pivotal) or one (1) Phase III study (evidence of safety and efficacy, pivotal) must be submitted for the Medical Director's review.")

Associated Documents

Attachments

N/A

Related Local Coverage Documents

Article(s)

A57707 - Billing and Coding: Treatment of Varicose Veins of the Lower Extremities

A54715 - Response to Comments: Treatment of Varicose Veins of Lower Extremities

A53079 - Sclerosing of Varicose Veins

Related National Coverage Documents

N/A

Public Version(s)

Updated on 01/29/2020 with effective dates 12/01/2019 - N/A

Updated on 11/08/2019 with effective dates 12/01/2019 - N/A

Updated on 12/07/2017 with effective dates 01/01/2018 - 11/30/2019

Updated on 12/06/2017 with effective dates 01/01/2018 - N/A

Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A